Dr. Jin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
200 1st St SW
Rochester, MN 55905Phone+1 507-284-2511
Summary
- Dr. Zhaohui Jin is an oncologist in Rochester, MN and is affiliated with Mayo Clinic Hospital - Rochester. He received his medical degree from Peking Union Medical College and has been in practice 21 years. He specializes in gastrointestinal cancer and hematologic oncology and is experienced in colorectal cancer and gastrointestinal oncology.
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2016 - 2017
University of Iowa Hospitals and ClinicsFellowship, Hematology and Medical Oncology, 2013 - 2016
Rutgers Health/Cooperman Barnabas Medical CenterResidency, Internal Medicine, 2011 - 2013- Rutgers Health/Cooperman Barnabas Medical CenterInternship, Internal Medicine, 2010 - 2011
Boston Children's HospitalPost-Doctoral Fellowship, 2005 - 2010
University of Florida College of MedicinePost-Doctoral Fellowship, 2002 - 2005
Peking Union Medical CollegeClass of 1996- University of Iowa Hospitals and ClinicsResidency, Internal Medicine
Certifications & Licensure
MN State Medical License 2016 - 2025
IL State Medical License 2017 - 2020
IA State Medical License 2013 - 2016
NJ State Medical License 2011 - 2015- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer Start of enrollment: 2020 Mar 03
Publications & Presentations
PubMed
- Second-line therapies in advanced hepatocellular carcinoma following first-line atezolizumab and bevacizumab: multicenter single institution cohort experience.Paulina Marell, Ioannis Kournoutas, Jennifer Gile, Anina Peersen, Priyanshi Shah
The Oncologist. 2024-12-14 - Fibroblast growth factor therapies in biliary tract cancers: current and future state.Teerada Siripoon, Conor O'Donnell, Zhaohui Jin, Amit Mahipal
Expert Opinion on Investigational Drugs. 2024-12-01 - 1 citationsAtezolizumab plus bevacizumab as first-line systemic therapy for hepatocellular carcinoma: a multi-institutional cohort study.Michael H Storandt, Tyler J Zemla, Kanchi Patell, Nikolas Naleid, Jennifer J Gile
The Oncologist. 2024-11-04
Journal Articles
- Systemic Therapy and Sequencing Options in Advanced Hepatocellular CarcinomaMohamad Bassam Sonbol, Amit Mahipal, Zhaohui Jin, Kabir Mody, Mitesh J Borad, Daniel H Ahn, Tanios Bekaii-Saab, JAMA Oncology
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
